KRONOS BIO INC. - COM

0,8576

08-октября-24 11:34:14

15 мин. задержка

Акции

-0,1324

-13,37%

Сегодняшний диапазон

0,8520 - 0,9800

ISIN

N/A

Источник

NASDAQ

Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study

02 ноя 2023 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

02 ноя 2023 11:00:00 Источник Nasdaq GlobeNewswire
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

27 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

13 окт 2023 11:30:00 Источник Nasdaq GlobeNewswire
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

04 окт 2023 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development

17 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results

08 авг 2023 15:05:03 Источник Nasdaq GlobeNewswire
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance

06 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in Upcoming Investor Conferences

01 июн 2023 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results

10 май 2023 15:05:02 Источник Nasdaq GlobeNewswire
Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors

24 апр 2023 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Changes to Board of Directors

11 апр 2023 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results

15 мар 2023 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference

28 фев 2023 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology

09 янв 2023 06:00:04 Источник Nasdaq GlobeNewswire
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting

11 дек 2022 09:00:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial

07 дек 2022 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in Upcoming Investor Conferences

22 ноя 2022 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results

08 ноя 2022 15:10:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

08 ноя 2022 15:05:02 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.